<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute bacterial prostatitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute bacterial prostatitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute bacterial prostatitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alain Meyrier, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Fekete, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The prostate is subject to various inflammatory disorders [<a href="#rid1">1</a>]. One of these syndromes is acute bacterial prostatitis, an acute infection of the prostate, usually caused by gram-negative organisms [<a href="#rid2">2</a>]. The clinical presentation is generally well defined, and antimicrobial therapy remains the mainstay of treatment [<a href="#rid3">3</a>].</p><p>Acute bacterial prostatitis will be reviewed here. Chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/86802.html" rel="external">"Chronic bacterial prostatitis"</a> and  <a class="medical medical_review" href="/z/d/html/6880.html" rel="external">"Chronic prostatitis and chronic pelvic pain syndrome"</a>.)</p><p>Other causes of dysuria in men, including cystitis, urethritis, and epididymitis, are also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">"Acute simple cystitis in adult and adolescent males"</a> and  <a class="medical medical_review" href="/z/d/html/86698.html" rel="external">"Urethritis in adult males"</a> and  <a class="medical medical_review" href="/z/d/html/6873.html" rel="external">"Acute scrotal pain in adults"</a>.)</p><p class="headingAnchor" id="H29437530"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Entry of microorganisms into the prostate gland almost always occurs via the urethra. In most cases, bacteria migrate from the urethra or bladder through the prostatic ducts, with intraprostatic reflux of urine  (<a class="graphic graphic_figure graphicRef54803" href="/z/d/graphic/54803.html" rel="external">figure 1</a>). As a result, there may be concomitant infection in the bladder or epididymis. Uropathogenic bacterial isolates that cause prostatitis may have a higher accumulation of specialized virulence factors than those involved in cystitis alone [<a href="#rid4">4,5</a>].</p><p>Acute prostatitis can also occur from direct inoculation after transrectal prostate biopsy and transurethral manipulations (eg, catheterization and cystoscopy) [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">"Prostate biopsy", section on 'Infection'</a>.)</p><p class="headingAnchor" id="H13503206"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Overall, prostatitis syndromes are a very common presentation in the clinical setting and tend to occur in young and middle-aged men [<a href="#rid3">3,8</a>]. However, acute bacterial prostatitis accounts for a minority of these cases.</p><p>In a study of 58,955 ambulatory visits to clinicians by men over the age of 18 years reported to the United States National Ambulatory Medical Care Surveys from 1990 to 1994, 5 percent listed genitourinary tract symptoms as one of the reasons for the visit [<a href="#rid9">9</a>]. Prostatitis was listed as a diagnosis in an estimated two million visits annually. Acute bacterial prostatitis, however, accounted for only 4 percent of prostatitis diagnoses.</p><p class="headingAnchor" id="H29437419"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Acute prostatitis can occur in the setting of cystitis, urethritis, or other urogenital tract infections. Thus, underlying conditions such as functional or anatomical anomalies (eg, urethral strictures), that predispose to other urogenital infections can increase the risk of prostatitis. </p><p>Prostate infections following urogenital instrumentation, including chronic indwelling bladder catheterization, intermittent bladder catheterization, and prostate biopsy are well documented [<a href="#rid10">10-12</a>]. As an example, in a retrospective study of 1339 men who underwent transrectal ultrasound-guided prostate biopsy, 28 men (2.1 percent) developed acute prostatitis a mean of three days post-biopsy, despite receiving periprocedural fluoroquinolone prophylaxis [<a href="#rid12">12</a>]. In another study, infection with drug-resistant bacteria was more common in prostatitis following transrectal prostate biopsy compared with spontaneous acute bacterial prostatitis [<a href="#rid13">13</a>]. Periprocedural antibiotic prophylaxis prior to prostate biopsy is generally recommended [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/8097.html" rel="external">"Prostate biopsy", section on 'Prophylactic antibiotics'</a>.)</p><p>Lower urinary tract symptoms, including those caused by bacterial prostatitis, also occur more frequently in patients with HIV infection than in the general population [<a href="#rid15">15,16</a>]. Why this occurs is not clear. While immunosuppression associated with HIV certainly increases the risk of prostatitis, HIV-infected men without AIDS-defining illnesses or low CD4 cell counts also report lower urinary tract symptoms more frequently than uninfected patients [<a href="#rid15">15</a>].</p><p>Many patients with acute bacterial prostatitis have no clear risk factors. Anecdotally, trauma (eg, bicycle or horseback riding), dehydration, and sexual abstinence have been thought to predispose to prostatitis. However, these factors have not been established by well-controlled studies.</p><p class="headingAnchor" id="H4"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>The pathogens associated with acute prostatitis reflect the spectrum of organisms causing cystitis, urethritis, and deeper genital tract infections (such as epididymitis). Thus, gram-negative infections, especially with Enterobacterales, are the most common [<a href="#rid17">17</a>]. Of Enterobacterales, <em>Escherichia coli</em> is the most typical, followed by <em>Proteus </em>species. As examples, in retrospective studies of men with acute bacterial prostatitis, such pathogens have been identified in positive urine cultures at the following frequencies [<a href="#rid6">6,7,18-21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>E. coli</em> – 58 to 88 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>Proteus</em> species – 3 to 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Other Enterobacterales (<em>Klebsiella</em>, <em>Enterobacter</em>, and <em>Serratia</em> species) – 3 to 11 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>Pseudomonas aeruginosa</em> – 3 to 7 percent</p><p></p><p>Certain gram-positive cocci (including <em>Staphylococcus aureus</em>, streptococci, and enterococci) have also been implicated in acute bacterial prostatitis [<a href="#rid18">18,19,22</a>]. Acute <em>staphylococcal prostatitis</em>, in particular, may result from bacteremia that accompanies a remote <em>S. aureus</em> infection elsewhere. Isolation of <em>S. aureus</em> from prostatic secretions should trigger an evaluation for a remote or endovascular staphylococcal infection.</p><p>Instrumentation of the prostate has been associated with subsequent acute bacterial prostatitis due to organisms with broad resistance to antibiotics, including fluoroquinolone-resistant <em>E. coli</em> and <em>Pseudomonas aeruginosa</em> [<a href="#rid11">11,18</a>]. This is likely related to the use of periprocedural prophylactic fluoroquinolones.</p><p>Sexually active men may have sexually transmitted urogenital infections, such as urethritis and epididymitis, which also acutely involve the prostate, in which case <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis </em>are important pathogens. (See  <a class="medical medical_review" href="/z/d/html/86698.html" rel="external">"Urethritis in adult males"</a>.) This problem tends to occur more often in younger men, but age is not a specific risk factor for these sexually transmitted infections.</p><p>In HIV-infected patients, the microbiology typically reflects that seen in the general population; however, involvement with other pathogens, including <em>Salmonella typhi</em> and <em>N. gonorrhoeae</em>, has also been described [<a href="#rid16">16</a>].</p><p>In patients or travelers from regions where <em>Burkholderia pseudomallei </em>is endemic (eg, southern and southeast Asia or northern Australia) this uncommon organism has also been described as a cause of acute prostatitis and prostatic abscess [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3146.html" rel="external">"Melioidosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p><em>Coccidioides </em>fungal prostatitis has been observed in hosts receiving immunosuppressive therapy [<a href="#rid25">25</a>].</p><p>Recurrent infection after completion of therapy is usually caused by the same organism that was found in the original infection [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical presentation of acute prostatitis is generally not subtle. Patients are typically acutely ill, with spiking fever, chills, malaise, myalgia, dysuria, irritative urinary symptoms (frequency, urgency, urge incontinence), pelvic or perineal pain, and cloudy urine. Men may also complain of pain at the tip of the penis. Swelling of the acutely inflamed prostate can cause voiding symptoms, ranging from dribbling and hesitancy to acute urinary retention. In a retrospective review of 614 cases of men who presented to an emergency department in Spain and were diagnosed with acute bacterial prostatitis, irritative symptoms were observed most commonly (93 percent), with obstructive symptoms (poor stream, hesitancy) and fever reported in 25 and 34 percent of patients, respectively [<a href="#rid18">18</a>]. No specific characteristics of urinary symptoms (eg, end-stream dysuria) have been clearly associated with prostatitis.</p><p>Rarely, patients lack these local symptoms and present instead with constitutional symptoms or a flu-like illness.</p><p>On exam, the prostate is often firm, edematous, and exquisitely tender. Common laboratory findings include peripheral leukocytosis, pyuria, bacteriuria, and, occasionally, positive blood cultures. Inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) are elevated in most cases. Inflammation of the prostate can also lead to an elevated serum prostate specific antigen (PSA) level [<a href="#rid27">27</a>]. Thus, if serum PSA testing for prostate cancer screening is planned, it should be deferred for one month following resolution of acute prostatitis. A detailed discussion of the risks and benefits of prostate cancer screening is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7568.html" rel="external">"Measurement of prostate-specific antigen"</a>.)</p><p class="headingAnchor" id="H13503467"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Complications of acute bacterial prostatitis include bacteremia, epididymitis, chronic bacterial prostatitis, prostatic abscesses, and metastatic infection (eg, spinal or sacroiliac infection) [<a href="#rid28">28</a>]. Patients with underlying valvular heart disease or a valvular prosthesis are at risk for endocarditis when prostatitis is caused by certain bacterial pathogens, particularly, but not exclusively, gram-positive bacteria. These complications are more likely to occur if diagnosis and antimicrobial therapy is delayed.</p><p class="headingAnchor" id="H23323139"><span class="h3">Prostatic abscess</span><span class="headingEndMark"> — </span>The incidence of prostatic abscess is currently low with the use of appropriate antibiotic therapy [<a href="#rid29">29</a>]. In a prospective study of transrectal ultrasonography of the prostate in 45 men hospitalized for acute bacterial prostatitis, no lesions with sonographic characteristics of prostatic abscesses were identified, despite detection of other, often transient, prostatic lesions in almost half of the men [<a href="#rid30">30</a>]. Certain underlying conditions, such as diabetes mellitus or HIV-related immunosuppression, may predispose to the development of prostatic abscesses [<a href="#rid31">31,32</a>].</p><p>Signs and symptoms of a prostatic abscess are similar to those of bacterial prostatitis in general, but may persist despite appropriate antibiotic therapy; in addition, fluctuance of the prostate on gentle digital exam can suggest an underlying abscess. On transrectal ultrasound, abscesses appear as hypoechoic or anechoic areas with thick walls or peripheral edema [<a href="#rid32">32,33</a>]. Computed tomography (CT) findings include nonenhancing fluid-density collections that can be multiseptated or rim-enhancing lesions.</p><p class="headingAnchor" id="H23323217"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The presence of typical symptoms of prostatitis should prompt digital rectal exam, and the finding of an edematous and tender prostate on physical exam in this setting usually establishes the diagnosis of acute bacterial prostatitis. Digital rectal examination should be performed gently; vigorous prostate massage should be avoided since it is uncomfortable, allows no additional diagnostic or therapeutic benefit, and increases the risk for bacteremia. In patients who present with constitutional symptoms only, establishing a diagnosis of acute prostatitis is challenging. Laboratory findings of leukocytosis, pyuria, bacteriuria, or an elevated serum prostate specific antigen (PSA) level can support the diagnosis, and should prompt consideration of digital rectal exam. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>In order to establish the microbial etiology, a urine Gram stain and culture should be obtained in all men suspected of having acute prostatitis. Gram stain of the urine, if positive, can be used as a guide to initial therapy (see <a class="local">'Antimicrobial therapy'</a> below). Urine culture typically reveals a causative organism in acute prostatitis, unless antibiotics were recently used.</p><p>Blood cultures usually are not necessary for microbial diagnosis, and we typically do not perform them for this reason alone. In a retrospective review of 261 men with acute prostatitis in whom urine and blood cultures were collected, blood cultures provided additional microbial information in 14 patients (5 percent) [<a href="#rid20">20</a>]. However, blood cultures are useful to assess for complications in patients with underlying cardiac valvular disease or clinical evidence of impending or severe sepsis.</p><p class="headingAnchor" id="H17630369"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H23323238"><span class="h2">Evaluation for complications</span><span class="headingEndMark"> — </span>Blood cultures to evaluate for bacteremia are warranted in patients with signs suggestive of severe sepsis (eg, hypotension, hematologic derangements). Additionally, a high level of suspicion for bacteremic complications of acute prostatitis is warranted in patients with underlying conditions that may predispose to them (eg, endocarditis in patients with valvular disease or prostheses).</p><p>In particular, when <em>S. aureus</em> is recovered from a urine culture, it is important to perform blood cultures to evaluate whether the bacteriuria reflects seeding of the prostate or urine from bacteremia. (See  <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">"Clinical manifestations of Staphylococcus aureus infection in adults"</a>.)</p><p>Imaging studies are generally not indicated in acute bacterial prostatitis, unless there is clinical suspicion for a prostatic abscess. In patients who have persistent clinical or laboratory abnormalities despite appropriate antimicrobial therapy, an abscess can be diagnosed radiographically with prostate ultrasonography or computed tomography (CT) scan [<a href="#rid34">34</a>]. (See <a class="local">'Complications'</a> above.)</p><p class="headingAnchor" id="H17630388"><span class="h2">Evaluation for anatomical abnormalities</span><span class="headingEndMark"> — </span>Following the acute episode, underlying anatomical abnormalities that may have predisposed to an acute prostatic infection may be sought and, if possible, remedied to decrease the risk of recurrence. Consultation with a urologist for this evaluation may be useful in patients with recurrent infections.</p><p class="headingAnchor" id="H172458394"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The most common alternate diagnosis to consider in a man who presents with dysuria, frequency, and/or urgency, and who has pyuria and bacteriuria, is an isolated lower urinary tract infection (UTI), or cystitis. UTIs in men generally occur in the presence of a predisposing functional or anatomic abnormality, such as prostatic hypertrophy or genitourinary instrumentation, which increases the risk of infection, although they can also uncommonly occur in otherwise healthy men. While isolated UTIs likely involve some amount of bacterial contamination along the prostatic ducts, this prostatic contamination may remain superficial without overt prostatic inflammation or suppuration. In such cases, fever, chills, and constitutional symptoms are generally absent, and there is no prostatic tenderness on digital rectal exam. Men who lack this evidence of clinically significant prostatic involvement can be managed as having acute simple cystitis but should be monitored for lack of clinical response, which would warrant reevaluation for the possibility of underlying prostatitis. (See  <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">"Acute simple cystitis in adult and adolescent males", section on 'Treatment'</a>.)</p><p>Tenderness of the prostate on exam is also generally not found in other acute causes of dysuria (eg, urethritis, epididymitis) in the absence of coexisting prostatitis.</p><p>Patients with conditions, such as benign prostatic hyperplasia and overactive bladder, may also initially present with lower urinary tract symptoms, but typically do not have fever, pyuria, and other signs or symptoms of infection. These conditions are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6889.html" rel="external">"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"</a> and  <a class="medical medical_review" href="/z/d/html/6879.html" rel="external">"Lower urinary tract symptoms in males"</a>.)</p><p class="headingAnchor" id="H23323367"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment of acute prostatitis includes antimicrobial therapy and supportive measures to reduce symptoms. Rarely, more invasive intervention is indicated to manage complications.</p><p class="headingAnchor" id="H23323375"><span class="h2">Indications for hospitalization</span><span class="headingEndMark"> — </span>Not all patients with acute bacterial prostatitis warrant inpatient hospitalization. Patients who have no major comorbidities, no signs or symptoms of severe sepsis, and who can reliably take and tolerate oral antibiotics, can likely be managed appropriately in the outpatient setting. A short hospital stay in patients suspected of having bacteremia, or for monitoring purposes in those patients who would not otherwise be able to promptly return to medical care in the case of decompensation, may be prudent. Acute urinary retention should also warrant very close observation or hospitalization for bladder catheterization.</p><p class="headingAnchor" id="H13503301"><span class="h2">Antimicrobial therapy</span></p><p class="headingAnchor" id="H2496053299"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>A variety of antimicrobials may be used for the treatment of acute prostatitis, which should be treated empirically pending culture results. Data on the treatment of acute prostatitis are limited, and there are no comparative trials evaluating the optimal antimicrobial choice. Thus, recommendations for empiric therapy are based on the likelihood of the infecting organism. Although not all antibiotics can penetrate into prostatic tissue, the presence of acute inflammation generally allows entry of drugs that would not otherwise achieve therapeutic levels. (See  <a class="medical medical_review" href="/z/d/html/86802.html" rel="external">"Chronic bacterial prostatitis", section on 'Antimicrobial penetration into prostatic tissue'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient empiric therapy</strong> – Empiric antibiotic therapy should adequately treat gram-negative organisms unless a urine Gram stain is available and suggests an alternate bacterial cause. For patients with acute prostatitis who can take oral medications, we suggest a fluoroquinolone (<a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 mg orally every 12 hours or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg orally once daily) or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (one double-strength tab orally every 12 hours) as empiric therapy. We typically choose one of these antimicrobial agents because they achieve high levels in prostatic tissue. Although this may not be an issue in the acute setting, where prostatic inflammation allows penetration of a broader range of antibiotics, the ability of an antibiotic to penetrate prostate tissue is thought to be important during prolonged therapy, while inflammation is resolving [<a href="#rid35">35</a>]. The choice between these should take into account patient tolerance and regional patterns of Enterobacteriaceae drug resistance. (See  <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females", section on 'Resistance trends in E. coli'</a>.)</p><p></p><p class="bulletIndent1">Men younger than 35 years who are sexually active and men older than 35 years who engage in high-risk sexual behavior should be treated with regimens that cover <em>N. gonorrhoeae </em>and <em>C. trachomatis </em>[<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Preferred regimen'</a> and  <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Doxycycline as preferred agent'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral empiric therapy for hospitalized patients</strong> – Some patients with acute bacterial prostatitis may need to be hospitalized for parenteral antibiotic therapy if they cannot tolerate oral medication, demonstrate signs of severe sepsis, or have bacteremia. </p><p></p><p class="bulletIndent1">In such cases, intravenous <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> may be given with or without an aminoglycoside (<a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> 5 mg/kg daily, if the creatinine clearance is normal). An intravenous beta-lactam with activity against Enterobacteriaceae with or without an aminoglycoside is an alternate initial regimen for hospitalized patients. The choice between these should take into account patient tolerance and regional patterns of Enterobacteriaceae drug resistance. </p><p></p><p class="bulletIndent1">Empiric treatment with an intravenous carbapenem or broad-spectrum penicillin or cephalosporin (with or without <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>) pending culture and sensitivity data is appropriate for patients who develop nosocomial prostatitis (eg, following a procedure for which they received a prophylactic fluoroquinolone) or who have a history of infections with drug-resistant pathogens, because of the increased risk of infection with a quinolone-resistant organism.</p><p></p><p>If available, a Gram stain of the urine can be helpful to further guide the empiric antibiotic choice:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with gram-negative rods on urine Gram stain should be treated as above.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-positive cocci in chains usually indicate enterococcal infection, which can be treated with <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (500 mg orally every eight hours) or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> (2 g intravenous every six hours) if parenteral therapy is indicated. Of note, these regimens are not active against most <em>Enterococcus faecium</em> or other ampicillin-resistant strains. (See  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-positive cocci in clusters are most often due to <em>Staphylococcus aureus</em> or coagulase-negative staphylococci (eg, <em>S. epidermidis</em> or <em>S. saprophyticus</em>). Effective oral antibiotics for strains that are not methicillin-resistant include cephalosporins (eg, <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> 500 mg orally every six hours) or penicillinase-resistant penicillins (eg, <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">dicloxacillin</a> 500 mg orally every six hours). Choices for parenteral therapy include <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> (1 g intravenous every eight hours) or <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> (2 g intravenous every four to six hours). If there are risk factors for, or a history of methicillin-resistant <em>S. aureus</em>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 1</a>) can be used. (See  <a class="medical medical_review" href="/z/d/html/3157.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology", section on 'Risk factors'</a>.)</p><p></p><p>Once culture and susceptibility data are available, the empiric regimen should be tailored to those results. Of note, although <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> is commonly used for lower urinary tract infections in women, we avoid this agent in men with prostatitis because of concern about poor tissue penetration and risk of adverse effects from prolonged use.</p><p>Data informing optimal antibiotic therapy of acute bacterial prostatitis are limited. In a study of 410 patients with microbiologically confirmed prostatitis the rate of fluoroquinolone resistance was 40 percent [<a href="#rid36">36</a>]. Nevertheless, initial therapy with a fluoroquinolone or an intravenous beta-lactam followed by tailoring the empiric regimen was associated with a lower risk of relapse compared with initial oral beta-lactam or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> therapy. Despite the inherent study design limitations, these data support fluoroquinolones as empiric therapy and highlight the importance of tailoring to culture results.</p><p class="headingAnchor" id="H172459038"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>Patients initiated on parenteral antibiotics can be switched to oral antibiotics, if drug susceptibility and patient tolerance allow, 24 to 48 hours following improvement in fever and clinical symptoms. We treat with antibiotics for up to six weeks to ensure eradication of the infection [<a href="#rid37">37</a>]. For patients who have no prostatic abscess and, with treatment, have a painless rectal examination, sterile urine, and normal inflammatory markers (erythrocyte sedimentation rate and C-reactive protein), stopping treatment at four weeks is reasonable. </p><p>Clinical data on the duration of treatment for acute bacterial prostatitis are limited, and some experts endorse a shorter duration [<a href="#rid22">22</a>]. We favor a relatively prolonged course because of limited antimicrobial penetration into the prostate and the development of protected microcolonies deep within the inflamed gland that may be difficult to reach with antimicrobials. Shorter durations of therapy have been associated with progression to chronic symptoms. (See <a class="local">'Prognosis'</a> below.) </p><p class="headingAnchor" id="H13503308"><span class="h2">Nonantimicrobial therapy</span><span class="headingEndMark"> — </span>Rarely, acute urinary retention develops during an episode of acute prostatitis. In this setting, we favor bladder drainage by suprapubic catheterization. Passage of a catheter through the inflamed urethra into the bladder in a patient with acute prostatitis risks septic shock or rupture of a potential abscess. Nevertheless, some experienced urologists do cautiously attempt urethral catheterization in these uncommon situations. (See  <a class="medical medical_review" href="/z/d/html/6883.html" rel="external">"Acute urinary retention", section on 'Urethral catheterization in most patients'</a>.)</p><p>In a patient with a prostatic abscess, urological referral is indicated if the abscess is persistent after one week or more of antimicrobial therapy. In some cases, ultrasound-guided or surgical drainage may be warranted.</p><p class="headingAnchor" id="H8"><span class="h2">Monitoring during therapy</span><span class="headingEndMark"> — </span>In most cases, fever abates and dysuria disappears within two to six days after the start of therapy. Acute phase reactants (eg, sedimentation rate, C reactive protein) and the PSA, if obtained, return to normal more gradually [<a href="#rid27">27</a>]. Clinical studies using a fluoroquinolone suggest that a negative urine culture at seven days following initiation of therapy predicts cure at the conclusion of the full course of therapy [<a href="#rid38">38</a>]. We typically repeat urine culture at seven days. If it is still positive at that time, alternative therapy should be initiated, based upon in vitro susceptibility tests of the most recent isolate.</p><p>Patients with persistently positive urine cultures should be further evaluated and treated for chronic bacterial prostatitis. (See  <a class="medical medical_review" href="/z/d/html/86802.html" rel="external">"Chronic bacterial prostatitis"</a>.)</p><p class="headingAnchor" id="H2080837959"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Progression from acute to chronic bacterial prostatitis or inflammatory chronic pelvic pain syndrome (CPPS) is poorly understood. In a prospective cohort of 437 Korean men who presented with a confirmed diagnosis of acute bacterial prostatitis, 82 percent recovered without subsequent development of chronic infection three months or longer after treatment [<a href="#rid39">39</a>]. Development of chronic bacterial prostatitis or inflammatory CPPS (observed in 1.3 and 10.5 percent, respectively) was associated with higher rates of alcohol consumption, diabetes, voiding symptoms, enlarged prostate volume, catheterization, and short (two weeks) duration of antibiotic treatment.</p><p class="headingAnchor" id="H16098359"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16550.html" rel="external">"Patient education: Bacterial prostatitis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1669378575"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology and risk factors</strong> – Acute bacterial prostatitis is an acute infection of the prostate that typically occurs in young and middle-aged men. In most men, it is generally caused by the same organisms that cause urinary tract infections, most commonly gram-negative bacteria, especially Enterobacteriaceae (typically <em>Escherichia coli</em> or <em>Proteus</em> species). Sexually transmitted pathogens, such as <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em>, are possible etiologies in sexually active men, who may have concomitant urethritis or epididymitis. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Patients with acute bacterial prostatitis are typically acutely ill. The most common symptoms and signs include fevers, chills, dysuria, pelvic or perineal pain, and cloudy urine. Obstructive symptoms, such as dribbling of urine, can also occur. On exam, the prostate is often firm, edematous, and exquisitely tender. Common laboratory findings include peripheral leukocytosis, pyuria, and bacteriuria. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Delay of antimicrobial therapy can increase the risk of secondary complications, including bacteremia, prostatic abscess, and metastatic infection (eg, spinal or sacroiliac infection, endocarditis). Certain underlying conditions, such as diabetes mellitus or HIV-related immunosuppression, may also predispose to the development of prostatic abscesses. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The presence of typical symptoms of prostatitis and the finding of an edematous and tender prostate on physical exam usually establishes the diagnosis. Digital rectal examination should be performed gently; vigorous prostate massage should be avoided since it is uncomfortable, allows no additional diagnostic or therapeutic benefit, and increases risk for bacteremia. Tenderness of the prostate on exam is generally not found in isolated UTIs or other acute causes of dysuria (eg, urethritis, epididymitis) in the absence of coexisting prostatitis. A urine culture should be obtained in all males suspected of having acute prostatitis to identify the bacterial etiology. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for imaging</strong> – Imaging studies are generally not warranted in acute bacterial prostatitis, unless there is clinical suspicion for a prostatic abscess (ie, when there are persistent clinical or laboratory abnormalities despite appropriate antimicrobial therapy). (See <a class="local">'Evaluation for complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antibiotic therapy</strong> – Most cases of acute bacterial prostatitis are caused by gram-negative organisms, and empiric antibiotic therapy should be directed against this class. We suggest empiric treatment with a fluoroquinolone or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), unless drug resistance is suspected. The choice between these should take into account patient tolerance and regional patterns of Enterobacteriaceae drug resistance. If a urine Gram stain is available and suggests an alternate bacterial cause, initial antibiotic therapy should be directed against the identified class of organism. Parenteral antimicrobial therapy is warranted in patients who cannot tolerate oral medications, demonstrate signs of severe sepsis, or have bacteremia. Further changes to the empiric antibiotic regimen should be made based on susceptibility data of the isolated organism and clinical response. (See <a class="local">'Antimicrobial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Directed antibiotic therapy and duration</strong> – Patients initiated on parenteral antibiotics can be switched to oral antibiotics, if drug susceptibility and patient tolerance allow, 24 to 48 hours following improvement in fever and clinical symptoms. We typically use a prolonged antibiotic course (eg, at least four weeks) to try to ensure eradication of the infection. If the urine culture is still positive at seven days, alternative therapy should be initiated, based upon in vitro susceptibility tests of the most recent isolate. (See <a class="local">'Duration of therapy'</a> above and <a class="local">'Monitoring during therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive measures</strong> – Adjunctive therapies include management of complications, such as acute urinary retention and prostatic abscesses. Passage of a catheter through the inflamed urethra into the bladder is contraindicated in patients with acute prostatitis. If needed, bladder drainage must be done by suprapubic catheterization. (See <a class="local">'Nonantimicrobial therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pontari MA, Joyce GF, Wise M, et al. Prostatitis. J Urol 2007; 177:2050.</a></li><li><a class="nounderline abstract_t">Gill BC, Shoskes DA. Bacterial prostatitis. Curr Opin Infect Dis 2016; 29:86.</a></li><li><a class="nounderline abstract_t">Coker TJ, Dierfeldt DM. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician 2016; 93:114.</a></li><li><a class="nounderline abstract_t">Johnson JR, Kuskowski MA, Gajewski A, et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis 2005; 191:46.</a></li><li><a class="nounderline abstract_t">Krieger JN, Dobrindt U, Riley DE, Oswald E. Acute Escherichia coli prostatitis in previously health young men: bacterial virulence factors, antimicrobial resistance, and clinical outcomes. Urology 2011; 77:1420.</a></li><li><a class="nounderline abstract_t">Kim SH, Ha US, Yoon BI, et al. Microbiological and clinical characteristics in acute bacterial prostatitis according to lower urinary tract manipulation procedure. J Infect Chemother 2014; 20:38.</a></li><li><a class="nounderline abstract_t">Ramakrishnan K, Salinas RC. Prostatitis: acute and chronic. Prim Care 2010; 37:547.</a></li><li><a class="nounderline abstract_t">Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282:236.</a></li><li><a class="nounderline abstract_t">Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159:1224.</a></li><li><a class="nounderline abstract_t">Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord 2002; 40:536.</a></li><li><a class="nounderline abstract_t">Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011; 78:511.</a></li><li><a class="nounderline abstract_t">Ozden E, Bostanci Y, Yakupoglu KY, et al. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology 2009; 74:119.</a></li><li><a class="nounderline abstract_t">Kim JW, Oh MM, Bae JH, et al. Clinical and microbiological characteristics of spontaneous acute prostatitis and transrectal prostate biopsy-related acute prostatitis: Is transrectal prostate biopsy-related acute prostatitis a distinct acute prostatitis category? J Infect Chemother 2015; 21:434.</a></li><li><a class="nounderline abstract_t">Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179:1379.</a></li><li><a class="nounderline abstract_t">Breyer BN, Van den Eeden SK, Horberg MA, et al. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J Urol 2011; 185:1710.</a></li><li><a class="nounderline abstract_t">Lee LK, Dinneen MD, Ahmad S. The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome. BJU Int 2001; 88:500.</a></li><li><a class="nounderline abstract_t">Cornia PB, Takahashi TA, Lipsky BA. The microbiology of bacteriuria in men: a 5-year study at a Veterans' Affairs hospital. Diagn Microbiol Infect Dis 2006; 56:25.</a></li><li><a class="nounderline abstract_t">Millán-Rodríguez F, Palou J, Bujons-Tur A, et al. Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol 2006; 24:45.</a></li><li><a class="nounderline abstract_t">Etienne M, Chavanet P, Sibert L, et al. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 2008; 8:12.</a></li><li><a class="nounderline abstract_t">Etienne M, Pestel-Caron M, Chapuzet C, et al. Should blood cultures be performed for patients with acute prostatitis? J Clin Microbiol 2010; 48:1935.</a></li><li><a class="nounderline abstract_t">Nagy V, Kubej D. Acute bacterial prostatitis in humans: current microbiological spectrum, sensitivity to antibiotics and clinical findings. Urol Int 2012; 89:445.</a></li><li><a class="nounderline abstract_t">Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis 2010; 50:1641.</a></li><li><a class="nounderline abstract_t">Heyse AM, Dierick J, Vanhouteghem H, et al. A case of imported melioidosis presenting as prostatitis. Infection 2003; 31:60.</a></li><li><a class="nounderline abstract_t">Morse LP, Moller CC, Harvey E, et al. Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. J Urol 2009; 182:542.</a></li><li><a class="nounderline abstract_t">Humphrey PA. Fungal prostatitis caused by coccidioides. J Urol 2014; 191:215.</a></li><li><a class="nounderline abstract_t">Smith JW, Jones SR, Reed WP, et al. Recurrent urinary tract infections in men. Characteristics and response to therapy. Ann Intern Med 1979; 91:544.</a></li><li><a class="nounderline abstract_t">Gamé X, Vincendeau S, Palascak R, et al. Total and free serum prostate specific antigen levels during the first month of acute prostatitis. Eur Urol 2003; 43:702.</a></li><li><a class="nounderline abstract_t">Siroky MB, Moylan R, Austen G Jr, Olsson CA. Metastatic infection secondary to genitourinary tract sepsis. Am J Med 1976; 61:351.</a></li><li><a class="nounderline abstract_t">Weinberger M, Cytron S, Servadio C, et al. Prostatic abscess in the antibiotic era. Rev Infect Dis 1988; 10:239.</a></li><li><a class="nounderline abstract_t">Horcajada JP, Vilana R, Moreno-Martínez A, et al. Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications. Scand J Infect Dis 2003; 35:114.</a></li><li><a class="nounderline abstract_t">Trauzzi SJ, Kay CJ, Kaufman DG, Lowe FC. Management of prostatic abscess in patients with human immunodeficiency syndrome. Urology 1994; 43:629.</a></li><li><a class="nounderline abstract_t">Ludwig M, Schroeder-Printzen I, Schiefer HG, Weidner W. Diagnosis and therapeutic management of 18 patients with prostatic abscess. Urology 1999; 53:340.</a></li><li><a class="nounderline abstract_t">Thornhill BA, Morehouse HT, Coleman P, Hoffman-Tretin JC. Prostatic abscess: CT and sonographic findings. AJR Am J Roentgenol 1987; 148:899.</a></li><li><a class="nounderline abstract_t">Chia JK, Longfield RN, Cook DH, Flax BL. Computed axial tomography in the early diagnosis of prostatic abscess. Am J Med 1986; 81:942.</a></li><li><a class="nounderline abstract_t">Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol 2011; 8:207.</a></li><li><a class="nounderline abstract_t">Marquez-Algaba E, Pigrau C, Bosch-Nicolau P, et al. Risk Factors for Relapse in Acute Bacterial Prostatitis: the Impact of Antibiotic Regimens. Microbiol Spectr 2021; 9:e0053421.</a></li><li><a class="nounderline abstract_t">Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother 2007; 8:1667.</a></li><li><a class="nounderline abstract_t">Arakawa S, Kamidono S. Assessment of the UTI criteria for bacterial prostatitis in Japan. Infection 1992; 20 Suppl 3:S232.</a></li><li><a class="nounderline abstract_t">Yoon BI, Han DS, Ha US, et al. Clinical courses following acute bacterial prostatitis. Prostate Int 2013; 1:89.</a></li></ol></div><div id="topicVersionRevision">Topic 8062 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509285" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26555038" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bacterial prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26926407" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute Bacterial Prostatitis: Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15593002" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459419" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute Escherichia coli prostatitis in previously health young men: bacterial virulence factors, antimicrobial resistance, and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462423" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Microbiological and clinical characteristics in acute bacterial prostatitis according to lower urinary tract manipulation procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20705198" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prostatitis: acute and chronic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10422990" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : NIH consensus definition and classification of prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9507840" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : How common is prostatitis? A national survey of physician visits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12235537" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Complications of intermittent catheterization: their prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21782225" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464043" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25701308" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical and microbiological characteristics of spontaneous acute prostatitis and transrectal prostate biopsy-related acute prostatitis: Is transrectal prostate biopsy-related acute prostatitis a distinct acute prostatitis category?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280509" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Best practice policy statement on urologic surgery antimicrobial prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420120" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : HIV status is an independent risk factor for reporting lower urinary tract symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11678742" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16713165" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The microbiology of bacteriuria in men: a 5-year study at a Veterans' Affairs hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437219" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18234108" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237098" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Should blood cultures be performed for patients with acute prostatitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095643" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute bacterial prostatitis in humans: current microbiological spectrum, sensitivity to antibiotics and clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20459324" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of bacterial prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12590337" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A case of imported melioidosis presenting as prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19524969" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24135439" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fungal prostatitis caused by coccidioides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/384858" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recurrent urinary tract infections in men. Characteristics and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767374" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Total and free serum prostate specific antigen levels during the first month of acute prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/986763" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Metastatic infection secondary to genitourinary tract sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3287559" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prostatic abscess in the antibiotic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12693562" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8165764" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management of prostatic abscess in patients with human immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9933051" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnosis and therapeutic management of 18 patients with prostatic abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3554922" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prostatic abscess: CT and sonographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3777003" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Computed axial tomography in the early diagnosis of prostatic abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21403661" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The etiology and management of acute prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34585972" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk Factors for Relapse in Acute Bacterial Prostatitis: the Impact of Antibiotic Regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17685884" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Therapy for prostatitis, with emphasis on bacterial prostatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1337062" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Assessment of the UTI criteria for bacterial prostatitis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24223408" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical courses following acute bacterial prostatitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
